Clinical observation of S-1 or docetaxel combined with nedaplatin in the moderate and advanced stages of esophageal cancer

Objective To investigate the efficacy and safety of S-1 combined with nedaplatin,do-cetaxel combined with nedaplatin plus concurrent radiotherapy in the treatment of moderate and advanced stages of esophageal cancer. Methods Fifty-six patients with the moderate and advanced stages of esopha-geal cancer were randomly divided into two groups：S-1 combined with nedaplatin,docetaxel combined with nedaplatin plus concurrent radiotherapy. Results The effective rate in the S-1 combined with nedapl-atin group and the docetaxel combined with nedaplatin group was 82. 1% and 85. 7%,the difference was not statistically significant. The main side effects were gastrointestinal reactions,myelosuppression,radio-active bronchitis,radioactive esophagitis,phlebitis. Docetaxel combined with nedaplatin had more the heavier myelosuppression,but it could be controlled after treatment. Conclusions Two concurrent chemo-radiation therapy program can be used. S-1 combined with nedaplatin has light toxic effects. Key words: Esophageal cancer;  Chemotherapy;  Radiotherapy;  S-1;  Docetaxel;  Nedaplatin